Home/Pipeline/Engineered Adenine Base Editors

Engineered Adenine Base Editors

Not specified

ResearchActive

Key Facts

Indication
Not specified
Phase
Research
Status
Active
Company

About Metagenomi

Metagenomi is pioneering a new era of genetic medicine by harnessing the vast diversity of microbial life through metagenomics to discover and engineer next-generation genome editing tools. Founded by pioneers in the field, the company has built an industry-leading database, identified over 20,000 editing systems, and is advancing a pipeline of in vivo therapies for genetic diseases. With a strong leadership team, strategic partnerships, and a public listing, Metagenomi is positioned to expand its therapeutic reach and translate its novel platform into transformative patient cures.

View full company profile

Other Not specified Drugs

DrugCompanyPhase
Inflammation ProgramsArcus BiosciencesNot Specified
Bone Marrow Conditioning ProgramTelix PharmaceuticalsPipeline
AGMB-447Agomab TherapeuticsNot Disclosed
AGMB-101Agomab TherapeuticsNot Disclosed
TRIFERTY-ATM®Laboratorio Reig JofreApproved/Commercial
AGEN1571 (anti-ILT2)AgenusNot specified
AGEN1777AgenusNot specified
AGEN1721AgenusNot specified
INCAGN1876 (GITR Agonist)AgenusNot specified
INCAGN1949 (OX40 Agonist)AgenusNot specified
AGEN1327 (anti-TIGIT)AgenusNot specified
AGEN2373 (CD137 Agonist)AgenusNot specified